Wclc
Entity.
- Evidence
- 28 documents · 8 separate publishers
- Standing
- Added automatically from coverage
- Time
- first seen 12 Sept 2026, last seen 7 Oct 2026
- Measured
- 11% of mentions say something specific about it; the rest only name it
- As of
- 8 Oct 2026
Where this comes from
- Clinical Trials Arena · 2026-10-07 · Taiho’s CMO Dr Keer on positive REZILIENT3 data for zipalertinib combo (opens the source in a new tab)
- The ASCO Post · 2026-10-05 · Relapsed or Refractory SCLC Phase I Study of Novel CAR T-Cell Therapy (opens the source in a new tab)
- The ASCO Post · 2026-10-05 · Metastatic PD-L1–High NSCLC Sacituzumab Govitecan/Pembrolizumab (opens the source in a new tab)
- The ASCO Post · 2026-10-02 · Advanced Lung Cancer Pumitamig Plus Elfetabart Drozuntecan (opens the source in a new tab)
- The ASCO Post · 2026-09-30 · Targeting B7-H3 in Second-Line SCLC Treatment Novel ADCs (opens the source in a new tab)
- The ASCO Post · 2026-09-29 · Mobile Lung CT Screening in Resource-Limited Settings BRELT3 (opens the source in a new tab)
- Inside Precision Medicine · 2026-09-24 · Signatera Surges in Liquid Biopsy Race with New Lung Cancer Data and a Japan Approval (opens the source in a new tab)
- The ASCO Post · 2026-09-24 · SCLC Tarlatamab Extended-Interval Dosing Regimens (opens the source in a new tab)
- The ASCO Post · 2026-09-22 · Metastatic HER2-Mutant NSCLC First-Line T-DXd (opens the source in a new tab)
- Fierce Pharma · 2026-09-19 · Fierce Pharma Asia—China deals safe from COINS?; Key WCLC data; Legend’s new CEO (opens the source in a new tab)
- PR Newswire · 2026-09-13 · Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026 (opens the source in a new tab)
- PR Newswire · 2026-09-12 · SystImmune, Inc. to Present New Global Data on Iza-bren (izalontamab brengitecan) in EGFR-mutated Non-Small Cell Lung Cancer at WCLC Congress 2026 (opens the source in a new tab)